Table 1

Demographic and clinical variables of the patients included in the analysis

VariableGlobal cohort (n=84)Tc-99m-MB (n=49)Tc-99m-ICG (n=35)P value
Age (years) (mean (95% CI))63.1 (60.5 to 65.7)63.0 (59.6 to 66.4)3.2 (59.1 to 67.3)0.935*
BMI (kg/m2) (mean (95% CI))30.7 (29.3 to 32.2)30.4 (28.4 to 32.4)31.2 (29.2 to 33.2)0.606*
Tumor maximum diameter (mm) (median (IQR))30.0 (18.0 to 42.0)31.0 (20.0 to 45.0)28.0 (18.0 to 42.0) 0.704†
Histology (n (%))0.860‡
 Endometrioid adenocarcinoma72 (85.7)41 (83.7)31 (88.6)
 Serous carcinoma7 (8.3)4 (8.2)3 (8.6)
 Carcinosarcoma2 (2.4)2 (4.1)0 (0.0)
 Mixed adenocarcinoma1 (1.2)1 (2.0)0 (0.0)
 Atypical hyperplasia2 (2.4)1 (2.0)1 (2.9)
Histologic grade (n (%))1.000‡
 G126 (31.0)15 (30.6)11 (31.4)
 G242 (50.0)25 (51.0)17 (48.6)
 G314 (16.7)8 (16.3)6 (17.1)
 Not applicable (EAH)2 (2.4)1 (2.0)1 (2.9)
Pre-operative risk (n (%))0.981‡
 Low49 (58.3)28 (57.1)21 (60.0)
 Intermediate20 (23.8)12 (24.5)8 (22.9)
 High11 (13.1)7 (14.3)4 (11.4)
 Not applicable (EAH)4 (4.8)2 (4.1)2 (5.7)
Lymphovascular invasion (n (%))0.814‡
 Yes22 (26.2)14 (28.6)8 (22.9)
 No60 (71.4)34 (69.4)26 (74.3)
 Not applicable (EAH)2 (2.4)1 (2.0)1 (2.9)
FIGO stage (n (%))0.800‡
 IA44 (52.4)25 (51.0)19 (54.3)
 IB15 (17.9)8 (16.3)7 (20.0)
 II14 (16.7)8 (16.3)6 (17.1)
 IIIA4 (4.8)2 (4.1)2 (5.7)
 IIIB0 (0.0)0 (0.0)0 (0.0)
 IIIC13 (3.6)3 (6.1)0 (0.0)
 IIIC22 (2.4)2 (4.1)0 (0.0)
 Not applicable (EAH)2 (2.4)1 (2.0)1 (2.9)
Surgical approach (n (%))0.001‡
 Laparotomy3 (3.6)3 (6.1)0 (0.0)
 Laparoscopy40 (47.6)30 (61.2)10 (28.6)
 Robotic41 (48.8)16 (32.7)25 (71.4)
Surgical procedure (n (%))0.238‡
 TH + SLNB3 (3.6)2 (4.1)1 (2.9)
 TH + BSO + SLNB45 (53.6)24 (49.0)21 (60.0)
 TH + BSO + uPLn5 (6.0)4 (8.2)1 (2.9)
 TH + BSO + bPLn8 (9.5)2 (4.1)6 (17.1)
 TH + BSO + bPLn + AoLn23 (27.4)17 (34.7)6 (17.1)
  • *Student t-test.

  • †Mann-Whitney U test

  • ‡Fisher exact test.

  • AoLn, para-aortic lymphadenectomy; BMI, body mass index; bPLn, bilateral pelvic lymphadenectomy; BSO, bilateral salpingo-oophorectomy; EAH, endometrial atypical hyperplasia; FIGO, International Federation of Gynecology and Obstetrics; SLNB, sentinel lymph node biopsy; TH, total hysterectomy; uPLn, unilateral pelvic lymphadenectomy.